STAINES-UPON-THAMES,
A conference call for investors will begin at 8:30 a.m. Eastern Time. The call can be accessed in three ways:
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the
CONTACTS
Investor Relations
Vice President, Finance and Investor Relations Officer
(314) 654-3638
daniel.speciale@mnk.com
Financial/Dailies Media Inquiries
H+K Strategies
Senior Vice President
813-545-2399
ron.bartlett@hkstrategies.com
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2020 Mallinckrodt. 07/2020
View original content to download multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-second-quarter-2020-301090457.html
SOURCE Mallinckrodt Pharmaceuticals